The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis
The meeting of the Russian Council of Experts for the use of the novel anabolic agent Forsteo®(teriparatide) to treat osteoporosis (OP) was held in Moscow on June 29, 2013. The meeting was attended by leading Russian OP specialists, including the members of the Russian Osteoporosis Association and i...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2013-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839574227145981952 |
|---|---|
| author | Olga Mikhailovna Lesnyak |
| author_facet | Olga Mikhailovna Lesnyak |
| author_sort | Olga Mikhailovna Lesnyak |
| collection | DOAJ |
| description | The meeting of the Russian Council of Experts for the use of the novel anabolic agent Forsteo®(teriparatide) to treat osteoporosis (OP) was held in Moscow on June 29, 2013. The meeting was attended by leading Russian OP specialists, including the members of the Russian Osteoporosis Association and its Presidium. The participants of the Council of Experts noted the great social importance of severe OP, which was associated primarily with its consequences, such as fractures causing an increase in disability and mortality rates in elderly people, and discussed the possibilities and benefits of the new approach to treating OP with teriparatide, the first drug permitting the formation of new bone tissue. The experts have recommended teriparatide for use within the registered indications in the following groups of patients: those who have severe OP (≥1 vertebral fractures, hip fracture of vertebral bodies or a fracture of the proximal femur, multiple recurrent fractures of skeletal bones) as first-line therapy; those who had ineffective previous antiosteoporotic therapy (new fractures occurring during the treatment and/or a continuing decline in bone mineral density), those who are intolerant to other medications for OP, or who have contraindications to their use. |
| format | Article |
| id | doaj-art-7e9ec6f8bb994d76b78b50648d03c41c |
| institution | Matheson Library |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2013-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-7e9ec6f8bb994d76b78b50648d03c41c2025-08-04T14:00:32ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2013-10-0173767810.14412/1996-7012-2013-2781807The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe OsteoporosisOlga Mikhailovna Lesnyak0Ural State Medical Academy, Ministry of Health of Russia, YekaterinburgThe meeting of the Russian Council of Experts for the use of the novel anabolic agent Forsteo®(teriparatide) to treat osteoporosis (OP) was held in Moscow on June 29, 2013. The meeting was attended by leading Russian OP specialists, including the members of the Russian Osteoporosis Association and its Presidium. The participants of the Council of Experts noted the great social importance of severe OP, which was associated primarily with its consequences, such as fractures causing an increase in disability and mortality rates in elderly people, and discussed the possibilities and benefits of the new approach to treating OP with teriparatide, the first drug permitting the formation of new bone tissue. The experts have recommended teriparatide for use within the registered indications in the following groups of patients: those who have severe OP (≥1 vertebral fractures, hip fracture of vertebral bodies or a fracture of the proximal femur, multiple recurrent fractures of skeletal bones) as first-line therapy; those who had ineffective previous antiosteoporotic therapy (new fractures occurring during the treatment and/or a continuing decline in bone mineral density), those who are intolerant to other medications for OP, or who have contraindications to their use.https://mrj.ima-press.net/mrj/article/view/502meeting of expertssevere osteoporosistreatmentteriparatide |
| spellingShingle | Olga Mikhailovna Lesnyak The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis Современная ревматология meeting of experts severe osteoporosis treatment teriparatide |
| title | The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis |
| title_full | The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis |
| title_fullStr | The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis |
| title_full_unstemmed | The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis |
| title_short | The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis |
| title_sort | russian council of experts for use of the innovative anabolic agent forsteo r teriparatide in the treatment of severe osteoporosis |
| topic | meeting of experts severe osteoporosis treatment teriparatide |
| url | https://mrj.ima-press.net/mrj/article/view/502 |
| work_keys_str_mv | AT olgamikhailovnalesnyak therussiancouncilofexpertsforuseoftheinnovativeanabolicagentforsteoteriparatideinthetreatmentofsevereosteoporosis AT olgamikhailovnalesnyak russiancouncilofexpertsforuseoftheinnovativeanabolicagentforsteoteriparatideinthetreatmentofsevereosteoporosis |